144 results on '"Arca M"'
Search Results
2. P2.16-06 A Phase 2 Study of Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Previously Treated ES-SCLC
3. OC 10.4 Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Nets Release Driver Thrombosis in Familial Hypercholesterolemia
4. Lipid management in patients with high and very high cardiovascular risk: Data from routine clinical practice in Europe (SANTORINI study)
5. Thrombocytopenia and kidney disease, two possible hallmark of FCS phenotype: Preliminary evidence from a cohort study
6. The smash program: An initiative for greater access to innovations for rare or severe hyperlipidemia
7. ApoB secretion and intracellular lipid content are modulated by ANGPTL3 and PCSK9 in HEPG2 cells
8. Investigation of the role of ANGPTL3 and PCSK9 in regulating the intracellular signaling in liver cells
9. Long-term efficacy and safety of lomitapide in patients with familial chylomicronemia syndrome (FCS): Data from the LOCHNES study
10. The contemporary management of patients with homozygous familial hypercholesterolemia: The experience of the Italian Lipigen registry and a systematic review of the literature
11. Lomitapide hepatic safety: A long term retrospective analysis in patients with homozygous familial hypercholesterolaemia
12. P490 MANAGEMENT OF SEVERE HYPERCHOLESTEROLEMIA IN ITALY: EVIDENCE FROM SANTORINI STUDY
13. Lomitapide in the long-term real-world management of HoFH – effectiveness, tolerability, and hepatic safety from the Pan-European study
14. Lomitapide effectively reduces triglyceride (TG) levels in familial chylomicronemia syndrome (FCS)
15. Lomitapide in the long-term real-world management of HoFH – effectiveness, tolerability, and hepatic safety data from the pan-European study
16. LDL-cholesterol levels and LDL polygenic score in a cohort of patients with clinically diagnosed familial hypercholesterolemia. Data from the LIPIGEN study
17. The genetic lack of ANGTPL3 does not alter HDL functionality
18. Role of NAFLD-associated genetic variants on renal function in patients with nonalcoholic fatty liver disease
19. Real-world use of PCSK9 inhibitors in familial hypercholesterolemia: Results from the Italian PCSK9i AIFA registries
20. Effects of patient characteristics on volanesorsen efficacy: Subgroup analysis of approach
21. ANGPTL3 and PCSK9 interact and show coordinated metabolic regulation in vitro
22. Experimental Investigation of Strength of Curved Beam by Thin Ply Non-Crimp Fabric Laminates
23. Experimental Observations of Dynamic Delamination in Curved [0] and [0/90] Composite Laminates
24. Experimental Investigation of the Effect of CNT Addition on the Strength of CFRP Curved Composite Beams
25. Application of ACMG guidelines for classification of variants detected in a cohort of patients with clinically suspected familial hypercholesterolemia (FH): Implication for the diagnosis.
26. Evaluation of the real-world efficacy effectiveness and safety of lomitapide in the management of HoFH: The European experience study
27. Evaluating the distribution of A 12 LDL-C raising variants score in patients with familial hypercholesterolemia
28. ANGPTL3 deficiency associates with expanded regulatory T cells with reduced lipid content
29. ANGPTL3 and PCSK9 interaction and modulation in feeding and fasting conditions using HEPG2 cellular model.
30. Atherosclerotic coronary artery disease burden by ct scan in subjects with molecularly defined heterozygous familial hypercolesterolemia (HEFH), polygenic familial hypercholesterolemia (PFH) and controls: A pilot study
31. The impact of ANGPTL3 deficiency on hepatic steatosis: Observations from carriers of loss-of-function mutations
32. Impaired HDL cholesterol efflux capacity in subjects with metabolically- but not genetically- driven non-alcoholic fatty liver disease (NAFLD)
33. Monogenic versus polygenic familial hypercholesterolemia: genetic risk score and response to treatment
34. Small and large bowel stenosis and atresias
35. Picosecond Absorption Saturation Dynamics of New [M(R,R’timdt)2] Metal-Dithiolenes
36. Evaluation Of Indices Of Glucose And Insulin Metabolism In A Coort Patients With Angptl3 Deficiency
37. Effects Of Angptl3 In C2C12 Muscle Cells: Results Of A Preliminary Study
38. Diagnosis Of Familial Hypercholesterolemia In The Clinical Practice: Performance Of Dutch Lipid Clinic Network Score
39. FH gene phenotypic expression: insight for therapeutic strategy
40. PCV101 - HYPERTRIGLYCERIDEMIA AND RISK OF ALL-CAUSE MORTALITY AND MAJOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) EVENTS IN CLINICAL PRACTICE: THE TG-REAL STUDY
41. Can monogenic severe hypertriglyceridemia be differentiated from polygenic forms through clinical features: data from approach and compass studies in fcs and non-fcs hypertriglyceridemic patients?
42. Assessing the disease burden among patients with familial chylomicronemia syndrome (FCS) on volanesorsen: Results of the re-focus study
43. Detection of familial chylomicronemia syndrome in a cohort of patients with severe hypertriglyceridemia through a next generation sequencing approach
44. Clinical and genetic features of familial hypercholesterolemia in pediatric patients: The lipigen Study
45. Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention
46. The APPROACH Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
47. Targeted sequencing of APOC3, GCKR, LIPA, PPP1R3b, NCAN, LYPLAL1 and TM6SF2 genes in patients with nonalcoholic fatty liver disease (NAFLD)
48. Response to treatment and occurrence of cardiovascular (cv) complications in patients with autosomal recessive hypercholesterolemia (arh): A retrospective analysis
49. ANGPTL3 facilitates β-adrenergic-dependent lipolysis in adipocytes: Evidence from in vitro studies
50. Response to treatment and occurrence of cardiovascular (CV) complications in patients with autosomal recessive hypercholesterolemia (ARH): A retrospective analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.